

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 December 2023 (07.12.2023)



(10) International Publication Number
WO 2023/233130 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) C07D 513/04 (2006.01)
C07D 487/04 (2006.01) C07D 519/00 (2006.01)
C07D 491/048 (2006.01) A61P 35/00 (2006.01)
C07D 495/04 (2006.01) A61K 31/519 (2006.01)

(21) International Application Number:

PCT/GB2023/051393

(22) International Filing Date:

26 May 2023 (26.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2207972.7 30 May 2022 (30.05.2022) GB
2215245.8 14 October 2022 (14.10.2022) GB

(71) Applicant: **ADORX THERAPEUTICS LIMITED**
[GB/—]; 137a George Street, Edinburgh EH2 4JY (GB).

(72) Inventors: **MCCARTHY, Clive**; c/o AdoRX Therapeutics Limited, 137a George St, Edinburgh, Central Scotland EH2 4JY (GB). **HEAP, Robert**; c/o Apex Molecular, Alderley Park, Alderley Edge, Cheshire SK10 4TG (GB). **WALKER, Edward**; c/o Evotec (UK) Ltd., Oxfordshire OX14 4RZ (GB). **MCMAHON, Pearl**; c/o Evotec (UK) Ltd., Oxfordshire OX14 4RZ (GB).

(74) Agent: **HGF LIMITED**; 1 City Walk, Leeds, West Yorkshire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: CD73 INHIBITOR COMPOUNDS



(57) Abstract: The present invention relates to compounds of formula I shown below: wherein R₁, X₂, X₃, X₄, X₅, X₆, X₇, X₈ and X₉ are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine CD73 activity is implicated, such as, for example, cancer.

WO 2023/233130 A1